Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug

Drug Metabolism and Disposition

Volumn 31, Issue 5, 2003, Pages 645-651

  Clement, Bernd ^a   Lopian, Katrin ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINE; AMIDOXIME; CARBOXYLESTERASE; CYTOCHROME B5; CYTOCHROME B5 REDUCTASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ETHYLMELAGATRAN; H 338 57; H 415 04; MELAGATRAN; N HYDROXYMELAGATRAN; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SUCCINATE DEHYDROGENASE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY MICROSOME; LIVER MICROSOME; LIVER MITOCHONDRION; NONHUMAN; PH; PRIORITY JOURNAL; REDUCTION; SWINE;

ADMINISTRATION, ORAL; AMIDINES; ANIMALS; AZETIDINES; BENZYLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTERS; GLYCINE; HUMANS; HYDROLYSIS; KIDNEY; LIVER; MICROSOMES; MITOCHONDRIA, LIVER; PRODRUGS; SWINE; THROMBIN;

ANIMALIA; SUS SCROFA;

EID: 0037403707     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.5.645     Document Type: Conference Paper

References (33)

1. Albert A, Goldacre R, and Phillips J (1948) The strength of heterocyclic bases. J Chem Soc 2240-2249.
2. Beattie DS (1968) Enzyme localization in the inner and outer membranes of rat liver mitochondria. Biochem Biophys Res Commun 31:901-907.
3. Clement B (1993) Methoden zur Behandlung und Prophylaxe der Pneumocystis carinii pneumonie (PCP) und anderen Erkrankungen sowie Verbindungen und Formulierungen zum Gebrauch bei besagten Methoden. German patent. P 4321444.4. PCT/DE 94/00756(1994): USA (5, 786, 383;28/6/1998); Europe (0708640, 16/9/1998).
4. Clement B (2002) Reduction of N-hydroxylated compounds: amidoximes (N-hydroxy-amidines) as pro-drugs of amidines. Drug Metab Rev 34:565-579.
5. Clement B, Demesmaeker M, and Linne S (1996) Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz. Chem Res Toxicol 9:682-688.
6. Clement B and Deters S (2000) Characterisation of the mitochondrial reductase involved in the activation of N-hydroxylated prodrugs. Arch Pharm 333 (Suppl 1):12.
7. Clement B, Immel M, Terlinden R, and Wingen FJ (1992) Reduction of amidoxime derivatives to pentamidine in vivo. Arch Pharm 325:61-52.
8. Clement B, Lomb R, and Möller W (1997) Isolation and characterization of the protein components of the liver microsomal O-insensitive NADH-benzamidoxime reductase. J Biol Chem 272:19615-19620.
9. Clement B and Mau S (1999) Reduction of amidoxime prodrugs and similar functional groups by extrahepatic tissues. Arch Pharm 332 (Suppl 2):31.
10. Clement B, Schmitt S, and Zimmermann M (1988) Enzymatic reduction of benzamidoxime to benzamidine. Arch Pharm 321:955-956.
11. Eriksson H, Eriksson UG, Frison L, Hansson PO, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd B. Stockelberg D, et al. (1999) Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 81:358-363.
12. Guengerich FP (1987) Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262:8459-8462.
13. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:612-651.
14. Gustafsson D, Nyström JE, Carlsson S, Bredberg U, Elg M, Gyzander E, Ungell AL, Antonsson T. Intr. by Hirsh J (1999) Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use. Blood 94 (10 Suppl I):26a.
15. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K-J, Ungell A-L, et al. (2001) The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171-181.
16. Hauptmann J (2002) Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. Eur J Clin Pharmacol 57:751-758.
17. Hauptmann J, Paintz M, Kaiser B, and Richter M (1988) Reduction of benzamidoxime denvative to the corresponding benzamidine in vitro and in vivo. Pharmazie 43:559-560.
18. Hirsh J. Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, and Brandt JT (1998) Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 114:445S-469S.
19. 3 25-hydroxylase (CYP2D25). J Biol Chem 275:34650-34655.
20. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, and Armstrong P (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855.
21. Kitamura S, Fukushi H, Miyawaki T, Kawamura M, Terashita Z-I, and Naka T (2001) Orally active GP IIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl) propanoyl]-3(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic acid. Chem Pharm Bull 49:268-277.
22. Kline ES, Brandt RB, Laux JE, Spainhour SE, Higgins ES, Rogers KS, Tinsley SB, and Waters MG (1986) Localization of L-lactate dehydrogenase in mitochondria. Arch Biochem Biophys 246:673-680.
23. Omura T and Sato R (1964) The carbon monoxide binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
24. Patterson LH (2002) Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 34:581-592.
25. 5 is modulated by its exposed heme edge. Biochemistry 37:1485-1494.
26. Schipper NGM, Osterberg T, Wrange U, Westberg C, Sokolowski A, Rai R, Young W, Sjoström B (2001) In vitro intestinal permeability of factor Xa inhibitors: influence of chemical structure on passive transport and susceptibility to efflux. Pharm Res (NY) 18:1735-1741.
27. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid Anal Biochem 150:76-85.
28. Sottocasa GL, Kuylenstierna B, Ernster L, and Bergstrand A (1967) An electron-transport system associated with the outer membrane of liver mitochondria. J Cell Biol 32:415-438.
29. Taniguchi H, Imai Y, and Sato R (1984) Role of the electron transfer system in microsomal drug monooxygenase catalyzed by cytochrome P-450. Arch Biochem Biophys 232:585-596.
30. van der Waterbeemd H, Smith DA, Beaumont K, and Walker DK (2001) Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
31. 5. J Am Chem Soc 110:6234-6240.
32. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, Hürzeler Müller M, Knoop D. Levet-Trafit B, Lipari MT, et al. (1996) 1. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 39:3139-3147.
33. Yasukochi Y and Masters BSS (1976) Some properties of a detergent-solubilized NADPHcytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251:5337-5344.